A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)

Trial Profile

A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2015

At a glance

  • Drugs Fingolimod (Primary) ; Influenza virus vaccine; Tetanus vaccine
  • Indications Influenza virus infections; Multiple sclerosis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 22 Oct 2011 Results presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 29 Jun 2011 Additional location [England] identified as reported by ClinicalTrials.gov.
    • 22 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top